Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection
Conditions
Interventions
JNJ-73763989
PegIFN-alpha-2a
+3 more
Locations
47
United States
Ruane Clinical Research Group Inc
Los Angeles, California, United States
UPMC Center For Liver Diseases
Pittsburgh, Pennsylvania, United States
Liver Institute Northwest
Seattle, Washington, United States
University of Calgary
Calgary, Alberta, Canada
GI Research Institute (G.I.R.I.)
Vancouver, British Columbia, Canada
Vancouver ID Research and Care Centre Society
Vancouver, British Columbia, Canada
Start Date
September 14, 2020
Primary Completion Date
August 29, 2023
Completion Date
February 13, 2024
Last Updated
June 24, 2025
NCT04166266
NCT06550622
NCT05922306
NCT05870969
NCT05630820
NCT04856085
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions